Sobi reçoit l’approbation de Santé Canada pour Empaveli™ (pegcétacoplan) pour le traitement de certains patients atteints d’hémoglobinurie paroxystique nocturne
December 09, 2022 11:00 ET
|
Sobi North America
Le premier traitement C3 ciblé approuvé au CanadaApprobation fondée sur les résultats de l’ étude de phase 3 comparative directe PEGASUS dans le cadre de laquelle Empaveli™ a démontré une supériorité...
Sobi Receives Approval from Health Canada for Empaveli™ (pegcetacoplan) for the Treatment of Certain Patients with Paroxysmal Nocturnal Hemoglobinuria
December 09, 2022 11:00 ET
|
Sobi North America
The first targeted C3 therapy approved in CanadaApproval based on results from head-to-head PEGASUS phase 3 study where Empaveli™ demonstrated superiority to eculizumab in improving hemoglobin...
U.S. Food and Drug Administration Issues Emergency Use Authorization for KINERET® (anakinra) for the Treatment of COVID-19-Related Pneumonia
November 10, 2022 07:00 ET
|
Sobi North America
Early treatment with KINERET reduced disease progression by 64 percent in hospitalized COVID-19 patientsi WALTHAM, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sobi North America, the North American...
Sobi to Present Data from REAL-HLH Study at the ACR Convergence 2022 Meeting
October 27, 2022 06:59 ET
|
Sobi North America
WALTHAM, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of the Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI), a specialized international...
Sobi Announces Launch of the INTO-HLH Registry, a Disease Registry for Patients with Hemophagocytic Lymphohistiocytosis (HLH)
June 28, 2022 08:00 ET
|
Sobi North America
WALTHAM, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Sobi® North America today announced the launch of the INTO-HLH Registry, a new disease registry for patients with hemophagocytic lymphohistiocytosis...
Nature Medicine publishes positive phase 3 anakinra study results in patients with COVID-19 pneumonia
September 07, 2021 08:00 ET
|
Sobi North America
WALTHAM, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and the Hellenic Institute for the Study of Sepsis today announce that Nature Medicine has...
FDA Approves KINERET® (anakinra) for the Treatment of Deficiency of IL-1 Receptor Antagonist (DIRA)
December 22, 2020 10:37 ET
|
Sobi North America
DIRA is an ultra-rare, autoinflammatory disease that typically presents in infancy and is characterized by life-threatening and painful skin and bone inflammation, intense, chronic pain and stunted...